Long-Term Intravitreal Dexamethasone Implant Outcomes in Uveitis

References

• Pelegrín L, Sainz de la Maza M, Molins B, Ríos J, Adán A. Long-term evaluationof dexamethasone intravitreal implant invitrectomized and non-vitrectomized eyes with macular edema secondary to non-infectious uveítis. Eye (Lond). 2015;29(7):943–950. doi:10.1038/eye.2015.73.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Callanan D, Dugel P, Godfrey DG, Goldstein DA, Wilensky JT. Treating chronic noninfectious posterior segment uveitis: the impact of cumulative damage. Proceedings of an expert panel roundtable discussion. Retina. 2006;26(suppl):1–16. doi:10.1097/01.iae.0000250601.15893.5f.
   PubMedGoogle Scholar
• Rhee DJ, Katrhyn A, Sobrin CL, Rapuano CJ. Ophthalmic Drug Guide. 2nd ed. London: Springer New York Dordrecht Heidelberg; 2011.
   Google Scholar
• De Smet MD, Taylor SR, Bodaghi B, et al. Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res. 2011;30(6):452–470. doi:10.1016/j.preteyeres.2011.06.005.
   PubMed Web of Science ®Google Scholar
• Zola M, Briamonte C, Lorenzi U, et al. Treatment of refractory uveitic macular edema: results of a first and second implant of long-acting intravitreal dexamethasone. ClinOphthalmol. Nov 2017;6(11):1949–1956.
   Google Scholar
• Hunter R, Lobo AM. Dexamethasone intravitreal implant for the treatment of noninfectious uveitis. ClinOphthalmol. 2011;5:1613–1621.
   Google Scholar
• Kane FE, Burdan J, Cutino A, Green KE. Iluvien: a new sustained delivery technology for posterior eye disease. Expert Opin Drug Delivery. 2008;5(9)::1039–1046. doi:10.1517/17425247.5.9.1039.
   PubMed Web of Science ®Google Scholar
• Lowder C, Belfort R Jr, Lightman S, et al. Dexamethasone intravitreal implant for non infectious intermediate or posterior uveitis.Ozurdex HURON study group. Arch Ophthalmol. May 2011;129(5):545–553. doi:10.1001/archophthalmol.2010.339.
   PubMed Web of Science ®Google Scholar
• Pohlmann D, Vom Brocke GA, Winterhalter S, Steurer T, Thees S, Pleyer U. Dexamethasone inserts in noninfectious Uveitis: A single-center experience. Ophthalmology. 2018;125(17):31574–31579. doi:10.1016/j.ophtha.2017.12.038.
   Google Scholar
• Palla S, Biswas J, Naesha CK. Efficacy of Ozurdex implant in treatment of noninfectious intermediate uveitis. Indian J Ophthalmol. 2015 Oct;63(10):767–770. doi:10.4103/0301-4738.171505.
   PubMed Web of Science ®Google Scholar
• De Smet MD. Corticosteroid intravitreal implants. Dev Ophthalmol. 2012;51(1):122–133. doi:10.1159/000336330.
   PubMedGoogle Scholar
• Lange C, Feltgen N, Junker B, et al. Resolving the clinical acuity categories “hand motion” and “counting fingers” using the Freiburg Visual Acuity Test (FrACT). Graefes Arch Clin Exp Ophthalmol. 2009;247(1):137–142. doi:10.1007/s00417-008-0926-0.
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;92(4):467–471. doi:10.1016/S0161-6420(85)34001-0.
   PubMed Web of Science ®Google Scholar
• Tomkins-Netzer O, Taylor SR, Bar A, et al. Treatment with repeat dexamethasone implants results in long-term disease control in eyes with noninfectious uveitis. Ophthalmology. 2014;121(8):1649–1654. doi:10.1016/j.ophtha.2014.02.003.
   PubMed Web of Science ®Google Scholar
• Bajwa A, Peck T, Reddy AK, Netland PA, Shidkrot Y. Dexamethasone implantation in birdshot chorioretinopathy-long-term outcome. Int Med Case Rep J. 2018;30(11):349–358. doi:10.2147/IMCRJ.S164206.
   Google Scholar
• Pohlman D, Winterhalter S, Pleyer U. Intravitreal dexamethasone for the treatment of CMO associated with refractory Sclerouveitis. Ocul Immunol Inflamm. 2018;26(1):160–165. doi:10.1080/09273948.2016.1196712.
   PubMed Web of Science ®Google Scholar
• Frere A, Caspers L, Makhoul D, Judice L. Single dexamethasone intravitreal implant in the treatment of noninfectious Uveitis. JOculPharmacolTher. May 2017;33(4):290–297.
   Web of Science ®Google Scholar
• Ratra D, Barh A, Banerjee M, et al. Safety and efficacy of intravitreal dexamethasone implant for refractory uveitic macular edemain adults and children. Ocul Immunol Inflamm. 2018;26(7):1034–1040. doi:10.1080/09273948.2018.1424342.
   PubMed Web of Science ®Google Scholar
• Garweg JG, Baglivo E, Freiberg FJ, et al. Response of postoperative and chronic uveitic cystoid macular Edema to a dexamethasone-based intravitrea implant (Ozurdex). J Ocul Pharmacol Ther. Sep 2016;32(7):442–450.
   PubMed Web of Science ®Google Scholar
• Zarranz-Ventura J, Carreño E, Johnston RL, et al. Multicenter study of intravitreal dexamethasone implantin noninfectious Uveitis: indications, outcomes, and reinjection frequency. Am J Ophthalmol. Dec 2014;158(6):1136–1145. doi:10.1016/j.ajo.2014.09.003.
   PubMed Web of Science ®Google Scholar
• Malcle A, Dot C, Voirin N, et al. Safety of intravitreal dexamethasone implant (ozurdex): the safodex study:. Incidence and risk factors of ocular hypertension. Retina. 2017;37(4):1352–1359. doi:10.1097/IAE.0000000000001369.
   PubMedGoogle Scholar
• Fassbender Adeniran JM, Jusufbegovic D, Schaal S. Common and rare ocular side-effects of the dexamethasone implant. Ocul Immunol Inflamm. 2017;25(6):834–840. doi:10.1080/09273948.2016.1184284.
   PubMed Web of Science ®Google Scholar
• Breitbach M, Rack D, Dietzel M, et al. Efficacy of a dexamethasone implant for the treatment of refractory cystoid macular edema in non-infectious uveitis. Klin Monbl Augenheilkd. May 2016;233(5):601–605. doi:10.1055/s-0042-102058.
   PubMed Web of Science ®Google Scholar
• Fonollosa A, Llorenç V, Artaraz J, et al. Safety and efficacy of intravitreal dexamethasone implants in the management of macular edema secondary to infectious uveitis. Retina. Sep 2016;36(9):1778–1785. doi:10.1097/IAE.0000000000001001.
   PubMed Web of Science ®Google Scholar
• Tsang AC, Virgili G, Abtahi M, et al. Intravitreal dexamethasone implant for the treatment of macular edema in chronic non-infectious Uveitis. Ocul Immunol Inflamm. Oct 2017;25(5):685–692. doi:10.3109/09273948.2016.1160130.
   PubMed Web of Science ®Google Scholar